Skip to Main Content

Paper Details

Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.
Med Oncol
5
2022
PSA, TET, TET-2, abiraterone, androgen, docetaxel, men, neutropenic, oligometastatic prostate cancer, patients, synchronous oligometastatic prostate cancer, testosterone
Author NameAffiliation
Bruce J TrockThe James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine
Phuoc T TranThe James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine
Phuoc T TranJohns Hopkins University School of Medicine
Phuoc T TranJohns Hopkins University School of Medicine
Christian P PavlovichThe James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine
Curtiland DevilleJohns Hopkins University School of Medicine
Stephen GrecoJohns Hopkins University School of Medicine
Danny Y SongJohns Hopkins University School of Medicine
Alan W PartinThe James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine
Oliver SartorTulane Cancer Center, Tulane University
Kenneth J PientaThe James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine
Kenneth J PientaJohns Hopkins University School of Medicine
  • 1 - 12

Datasets

Release 1.2